Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Front Immunol. 2024 Aug 15;15:1449291. doi: 10.3389/fimmu.2024.1449291. eCollection 2024.
Cancer dissemination to lymph nodes (LN) is associated with a worse prognosis, increased incidence of distant metastases and reduced response to therapy. The LN microenvironment puts selective pressure on cancer cells, creating cells that can survive in LN as well as providing survival advantages for distant metastatic spread. Additionally, the presence of cancer cells leads to an immunosuppressive LN microenvironment, favoring the evasion of anti-cancer immune surveillance. However, recent studies have also characterized previously unrecognized roles for tumor-draining lymph nodes (TDLNs) in cancer immunotherapy response, including acting as a reservoir for pre-exhausted CD8+ T cells and stem-like CD8+ T cells. In this review, we will discuss the spread of cancer cells through the lymphatic system, the roles of TDLNs in metastasis and anti-cancer immune responses, and the therapeutic opportunities and challenges in targeting LN metastasis.
癌症向淋巴结(LN)的扩散与预后更差、远处转移发生率增加以及对治疗的反应降低有关。LN 微环境对癌细胞施加选择性压力,产生能够在 LN 中存活的细胞,并为远处转移扩散提供生存优势。此外,癌细胞的存在导致 LN 微环境的免疫抑制,有利于逃避抗肿瘤免疫监视。然而,最近的研究也描述了肿瘤引流淋巴结(TDLNs)在癌症免疫治疗反应中的先前未被认识的作用,包括作为耗尽的 CD8+T 细胞和类干细胞 CD8+T 细胞的储存库。在这篇综述中,我们将讨论癌细胞通过淋巴系统的扩散、TDLNs 在转移和抗肿瘤免疫反应中的作用,以及靶向 LN 转移的治疗机会和挑战。
Front Immunol. 2024
Front Immunol. 2025-4-11
Cell Oncol (Dordr). 2024-4
Clin Exp Metastasis. 2024-8
Trends Cancer. 2024-1
Cells. 2021-3-12
Mater Today Bio. 2025-6-27
Int J Mol Sci. 2025-3-5
Int J Med Sci. 2025-2-18
Mater Today Bio. 2024-4-26
Nat Biomed Eng. 2024-10
Science. 2024-4-26
Nat Rev Cancer. 2024-6
N Engl J Med. 2024-4-4